SCHEMBL21932071

SCHEMBL21932071

CNC(=O)OCCN(c1ccc(N)cc1)S(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 4/20 0.41
MMP9 P14780 4/20 0.41
PHLPP2 Q6ZVD8 1/20 0.40
MAOA P21397 2/20 0.39
HTR3A P46098 2/20 0.39
HRH3 Q9Y5N1 2/20 0.39
CYP2D6 P10635 1/20 0.39
TSHR P16473 1/20 0.39
BLM P54132 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM3 P20309 1/20 0.34
HTR2C P28335 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4492356 0.76 KMT2A (0.51) MMP2MMP9TSHRSMN1; SMN2KMT2A
SCHEMBL5627355 0.73 MTNR1A (0.45) MMP2MMP9TSHRBLMSMN1; SMN2
SCHEMBL2994448 0.73 ALDH1A1 (0.44) MMP2MMP9CYP2D6TSHRNPSR1
SCHEMBL21932070 0.73 SMN1; SMN2 (0.41) MMP2MMP9SMN1; SMN2KMT2AL3MBTL1
SCHEMBL6327814 0.72 MMP2 (0.43) MMP2MMP9MAOATSHRSMN1; SMN2
SCHEMBL5626036 0.71 MMP2 (0.39) MMP2MMP9PHLPP2TSHRSMN1; SMN2
SCHEMBL10192202 0.71 MMP2 (0.53) MMP2MMP9NPSR1KMT2ANPC1
SCHEMBL3150048 0.71 CYP3A4 (0.42) MMP2MMP9PHLPP2TSHRSMN1; SMN2
SCHEMBL29623674 0.71 LMNA (0.46) MMP2MMP9PHLPP2MAOAHTR3A
SCHEMBL6318614 0.70 ALDH1A1 (0.48) MMP2MMP9MAOATSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987558-B1 ALK5 inhibitors and their uses SYNTHIS THERAPEUTICS, INC. (US) 2024-05-21 US disclosed
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2023-05-04 US disclosed
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF SYNTHIS THERAPEUTICS, INC. (US) 2023-03-23 US disclosed
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses SYNTHIS THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2022-08-11 US disclosed
US-20210299268-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2021-09-30 US disclosed
EP-3820467-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES Synthis Therapeutics, Inc. (US) 2021-05-19 EP disclosed
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987558-B1 ALK5 inhibitors and their uses ALK, ALKBH3, ALKBH5 MMP2 2307/4885MMP9 1930/4885PHLPP2 580/4885
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 MMP2 2859/4885MMP9 2318/4885PHLPP2 1276/4885
US-20210299268-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 MMP2 2859/4885MMP9 2318/4885PHLPP2 1276/4885
US-20230090552-A1 ALK5 INHIBITOR CONJUGATES AND USES THEREOF ALK, ALKBH5, ALKBH3 MMP2 2654/4885MMP9 1754/4885PHLPP2 816/4885
US-11583593-B2 Antibody-ALK5 inhibitor conjugates and their uses ALK, ALKBH5, ALKBH3 MMP2 2859/4885MMP9 2318/4885PHLPP2 1276/4885
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 MMP2 2859/4885MMP9 2318/4885PHLPP2 1276/4885
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 MMP2 2859/4885MMP9 2318/4885PHLPP2 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.